Fentanyl & Federal Fallout: DEA Whistleblower Saga Alleges Retaliation

POLICY WIRE — Albuquerque, United States — It’s never about the drugs; it’s about the truth, and sometimes, the price of that truth runs staggeringly high within the sterile corridors of federal law enforcement. An aging, seasoned lawman, once embedded in the frontline fight against narcotics, has found himself caught in the crosshairs not of kingpins or cartels, but of his own agency—the Drug Enforcement Administration. His alleged sin? Standing shoulder-to-shoulder with a colleague who dared to speak out about something as incendiary as compromised fentanyl operations. This isn’t just a squabble among desk jockeys; it hints at rot, deep and unsettling, inside an organization tasked with protecting the nation from lethal drugs.

Kevin Small, a retired DEA special agent currently contracting with the Albuquerque district office, contends he’s faced a calculated campaign of professional purgatory. His attorneys, led by Tristan Leavitt of Empower Oversight—a firm not unfamiliar with high-stakes federal whistleblowing cases—didn’t mince words, firing off a letter to the U.S. Department of Justice Office of Inspector General. They’re demanding an immediate, full-bore investigation into what they describe as unequivocal retaliation.

Small’s troubles, it seems, began after he threw his weight behind DEA Special Agent David Howell. And Howell, bless his bureaucratic heart, wasn’t alleging petty misconduct. Oh no. Back in 2023, he voiced severe reservations, claiming fellow agents weren’t following protocol related to fentanyl investigations. This wasn’t just a paperwork error; Howell asserts they allowed large fentanyl shipments into New Mexico. Think about that for a second. Allowed. The reason? To build stronger criminal cases. A tactical gambit, perhaps, but one that raises questions about public safety versus prosecution strategies—and it certainly opens a Pandora’s box of ethical considerations.

Because he sided with Howell, Small alleges, his world changed overnight. Initially, he claims, he was cut off from vital intelligence—not allowed access to certain information in the Albuquerque office. But it really turned sour after Howell, fed up, went public with his accusations in late June of 2026. Suddenly, the heat ratcheted up. Small alleges that’s when the top dog in Albuquerque, Assistant Special Agent in Charge Jeffrey Armijo, summoned him to his sanctum. And, according to Small, ASAC Armijo’s message was chillingly direct: “if you support David Howell, we’re through.” Small maintains he made his position clear, telling Armijo he supported Howell and his revelations. He described that tête-à-tête as a “tense conversation”—a classic understatement for a career-ender, I reckon.

The punitive actions, as outlined in the letter, snowballed quickly. The DEA allegedly slapped strict work hours on him, ripping away the flexibility of his part-time status. He was forced into mandatory reporting of every minutiae of his workday, a bureaucratic handcuff if ever there was one. But wait, there’s more. ASAC Armijo, Small claims, then gave an order to DEA agents to not give Small any further work. No work? In an agency drowning in caseloads, that’s not just an insult; it’s a professional death sentence. Ultimately, the letter concludes that the relentless hostility and retaliation Small faced from ASAC Armijo left him with exactly one option: to submit his resignation, which will kick in at the end of next month. Small had no choice, his lawyers say.

This isn’t a new story in the world of federal bureaucracy. The whistleblowers, those inconvenient moral compasses, often pay the steepest price. This isn’t unique to America, either. Around the globe, from the fledgling anti-corruption agencies in places like Pakistan—where even exposing minor graft can have profound personal consequences—to developed nations, individuals who shine a light on institutional darkness frequently find themselves isolated and ostracized. It’s a universal pattern, this human tendency to silence uncomfortable truths, especially when they emanate from within the system.

Leavitt, who’s not only representing Small but also Howell in his broader whistleblower case, isn’t backing down. He’s pushing for a swift — and comprehensive investigation by the DOJ’s Office of Inspector General. The stakes here couldn’t be higher. In an age where drug cartels flood our streets with synthetic opioids, allegations that DEA agents deliberately allowed massive fentanyl shipments through in the interest of ‘stronger cases’ are not just alarming—they’re scandalous. It’s reported that over 70,000 Americans died from fentanyl-related overdoses in 2021 alone, according to the Centers for Disease Control and Prevention; this isn’t a statistic one can casually ignore in pursuit of a better bust.

We’ve reached out to the DEA — and the Office of the U.S. Attorney of New Mexico for comment on these damning allegations. And, wouldn’t you know it, we haven’t heard back yet. Perhaps they’re just weighing their words. Or perhaps they’re hoping it’ll all just quietly disappear, swallowed by the ceaseless news cycle, just like another unwanted truth.

What This Means

The implications of this alleged bureaucratic bloodbath are far-reaching. Politically, this case could ignite renewed scrutiny on federal agencies’ internal oversight mechanisms. If even retired agents, working as contractors, can face such intense blowback for simply supporting a colleague, it chills the atmosphere for any current employee contemplating exposing wrongdoing. This dynamic undermines not just the DEA’s integrity but also public trust in the government’s ability to police itself. Economically, a weakened whistleblower protection system can lead to vast inefficiencies and corruption going unchecked, potentially costing taxpayers millions through misconduct, unchecked contracts, and compromised operations. The illicit drug trade, for example, is a multi-billion dollar industry; if the very agencies combating it are allegedly compromised at such fundamental levels, it only empowers criminal enterprises. For the broader geopolitical landscape, particularly nations like those in South Asia frequently grappling with drug transit and associated corruption—think heroin flows through Afghanistan and Pakistan, or synthetic routes affecting many Muslim-majority nations—this American scenario serves as a stark reminder. It highlights the pervasive challenge of maintaining clean hands in dirty battles, a battle against substances that respects no borders or bureaucracy. Any breakdown in integrity, no matter how local, contributes to a global erosion of faith in institutions. It begs the question: are federal law enforcement agencies doing enough to safeguard those who speak truth to power, especially when that power might be putting dangerous narcotics on the streets, even in pursuit of bigger targets? It’s a balancing act, sure, but a very precarious one, especially when lives hang in the balance. The stakes are always higher than they seem; just like talent acquisition, trust is hard-earned and easily lost.